Active	Status	Sponsor type	Region	Phase	Filter
2 Active 4 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Silverman, Joshua
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma	Active, not recruiting	2	247	US	SurVaxM	MimiVax, LLC, Translational Drug Development, Merit	Newly Diagnosed Glioblastoma	08/24	08/24
Polsky, David
SpotCheck, NCT04411810: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer	Completed	N/A	149	US	Nevisense 3.0, Dermlite Cam, Skin biopsy, Barco Demetra	NYU Langone Health	Skin Cancer	03/23	03/23
Patel, Amie
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Silverman, Joshua
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma	Active, not recruiting	2	247	US	SurVaxM	MimiVax, LLC, Translational Drug Development, Merit	Newly Diagnosed Glioblastoma	08/24	08/24
Polsky, David
SpotCheck, NCT04411810: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer	Completed	N/A	149	US	Nevisense 3.0, Dermlite Cam, Skin biopsy, Barco Demetra	NYU Langone Health	Skin Cancer	03/23	03/23
Patel, Amie
No trials found